VTYX
Ventyx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.00
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 87.7M | 117.0M | 175.8M | 87.7M | 58.5M |
| SG&A Expense | 29.0M | 31.4M | 32.2M | 25.4M | 8.7M |
| General & Admin Expense | 29.0M | 31.4M | 32.2M | 25.4M | 8.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 116.7M | 148.4M | 208.0M | 113.1M | 67.1M |
| Cost and Expenses | 116.7M | 148.4M | 208.0M | 113.1M | 67.1M |
| Operating Income (EBIT) | (116.7M) | (148.4M) | (208.0M) | (113.1M) | (67.1M) |
| Non-Operating | |||||
| Interest Income | 10.1M | 13.4M | 15.1M | 4.7M | 78.0K |
| Interest Expense | — | — | — | — | 99.0K |
| Net Interest Income | 10.1M | 13.4M | 15.1M | 4.7M | (21.0K) |
| Other Non-Op Income/Expense | 10.1M | 13.3M | 15.0M | 4.7M | (16.6M) |
| Non-Operating Income (excl Interest) | (2.0M) | — | — | — | 16.5M |
| EBT (Pre-Tax Income) | (106.6M) | (135.1M) | (193.0M) | (108.4M) | (83.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (106.6M) | (135.1M) | (193.0M) | (108.4M) | (83.7M) |
| Earnings from Cont. Ops | (106.6M) | (135.1M) | (193.0M) | (108.4M) | (83.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (106.6M) | (135.1M) | (193.0M) | (108.4M) | (85.3M) |
| Per Share | |||||
| Basic EPS | ($1.50) | ($1.97) | ($3.30) | ($2.06) | ($1.69) |
| Diluted EPS | ($1.50) | ($1.97) | ($3.30) | ($2.06) | ($1.69) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 71.3M | 68.5M | 58.5M | 52.5M | 50.4M |
| Diluted Shares Outstanding | 71.3M | 68.5M | 58.5M | 52.5M | 50.4M |
| Profitability Metrics | |||||
| EBITDA | (113.6M) | (147.1M) | (207.1M) | (112.7M) | (83.6M) |
| D&A | 1.1M | 1.3M | 941.0K | 470.0K | 30.0K |
| EBIT | (114.7M) | (148.4M) | (208.0M) | (113.1M) | (83.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025